Welcome! Thank you for visiting the Diurnal website. It is an honour for me to introduce you to our company and ethos and to emphasise our on-going commitment to developing high-quality hormone therapeutics for patients with chronic endocrine conditions.

At Diurnal, patients are at the forefront of everything we do. Since our inception in 2004, our mission has been clear: to address crucial unmet patient and clinical need in the endocrine field and to deliver the best health outcomes to improve patients’ quality of life.

How are we achieving this? By continuing to harness and channel the passion, knowledge and expertise of our team to create and develop a unique and highly specialised pipeline of products that focus on meeting patient needs.

In 2017, we built upon the successful Phase III studies of our lead product, Alkindi® (hydrocortisone granules in capsules for opening), completed a year earlier. The European Medicines Agency authorised Alkindi® as replacement therapy of adrenal insufficiency in patients aged from birth to 18 years. This is a credit to the hard work of patients, investigators, the Diurnal team and our collaborators that helped develop Alkindi®, and demonstrates that we can successfully develop first-in-class medicine formulations to treat diseases of cortisol deficiency.

2018 promises to be a transformational year in the evolution of our company, with the marketing authorisation approval of Alkindi® in Europe (announced February 2018), the launch and commercialisation of Alkindi®, the anticipated read out of our pivotal Phase III study in congenital adrenal hyperplasia of our second candidate product, Chronocort®, and subsequent progression into adrenal insufficiency.

These are exciting times for our organisation! We are delighted to have started the year with our first product approval, which is a significant step forwards in our vision to create novel treatments for rare diseases in the endocrine field.

Through our unfaltering commitment and drive, my ambition is for Diurnal to be a global leader in specialist endocrine products. I promise that Diurnal will continue to strive to deliver products of the highest quality and efficacy for patients with chronic endocrine conditions, to enable them to lead healthier, happier and more active lives.

It is my hope that your visit to our website is the first all-important step on that road.

Martin Whitaker
Chief Executive Officer